Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 424,900 shares, a decline of 20.5% from the October 31st total of 534,200 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is presently 0.2 days.

Mustang Bio Stock Up 5.0 %

Mustang Bio stock opened at $0.20 on Monday. The company has a market capitalization of $9.53 million, a PE ratio of -0.13 and a beta of 1.92. The firm’s fifty day moving average is $0.24 and its 200 day moving average is $0.30. Mustang Bio has a 12-month low of $0.13 and a 12-month high of $1.66.

Mustang Bio (NASDAQ:MBIO) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. Sell-side analysts expect that Mustang Bio will post -0.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MBIO. Virtu Financial LLC bought a new stake in Mustang Bio during the 1st quarter valued at $31,000. Koss Olinger Consulting LLC acquired a new position in shares of Mustang Bio during the second quarter valued at about $47,000. Finally, Thoroughbred Financial Services LLC bought a new stake in shares of Mustang Bio during the second quarter worth about $25,000. Institutional investors own 9.95% of the company’s stock.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.